A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Two non­prof­it or­ga­ni­za­tions are team­ing up for a gi­ant study of an ex­per­i­men­tal vac­cine de­signed to pro­tect against the world’s dead­liest in­fec­tious dis­ease.

The Bill and Melin­da Gates Foun­da­tion and Well­come are com­mit­ting $550 mil­lion to fund a Phase III clin­i­cal tri­al of an ex­per­i­men­tal tu­ber­cu­lo­sis vac­cine de­vel­oped by GSK. If the shot proves suc­cess­ful, it could be the first new vac­cine for pre­vent­ing the dead­ly bac­te­r­i­al lung in­fec­tion in more than 100 years.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN